Approval by the fda and could be available to mrcc patients as soon as 2016. generic viagra online About the arcelis™ technology arcelis is a fully personalized, active immunotherapy technology that captures all antigens, including mutated and variant antigens that are specific to each patient´s disease. It has been shown to overcome immunosuppression by producing a durable memory t-cell response without adjuvants that are associated with toxicity. cheap generic viagra The technology can be leveraged to manufacture personalized therapies for any cancer or infectious disease. The arcelis process integrates readily into many current treatment paradigms by using only a small tumor or blood sample and the patient´s own dendritic cells, which are derived and then optimized following a single leukapheresis procedure. The proprietary process uses rna isolated from the patient sample to program the dendritic cells to target the entire disease-antigen repertoire. viagra coupon The activated, antigen-loaded dendritic cells are then formulated into the patient´s plasma and administered as an injection into the skin to produce the desired patient-specific immune response. Arcelis technology also overcomes many of the manufacturing and commercialization challenges that have impeded other cancer immunotherapies. viagra safe ace inhibitors Automated processes allow a single facility to serve all of north america and can be used to treat any cancer or infectious disease with the same manufacturing process and equipment. cheap viagra online About argos therapeutics argos therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its arcelis™ technology platform. viagra blood pressure control Argos´ most advanced product candidate ags-003 has initiated a phase 3 study for the treatment of mrcc, and the company plans to have top line data from its phase 2b study of ags-004 for the treatment of hiv in the second half of 2013. usual dose viagra Argos also recently completed a successful phase 1a study of ags-009 in patients with lupus. viagra online without prescription Contact: the ruth group victoria aguiar (media) vaguiar@theruthgroup. usual dose viagra Com (646) 536-7013 nicole greenbaum (investors) ngreenbaum@theruthgroup. buy herbal viagra online uk Com (646) 536-7009 argos therapeutics jeff abbey (partners) jabbey@argostherapeutics. Com (919) 287-6308 other company press releases argos therapeutics invited to present at two biotech industry conferences - sep 27, 2012 08:01 et argos therapeutics to present at noble financial capital markets' biox life sciences exposition - sep 20, 2012 08:01 et argos therapeutics expands global patent protection - sep 6, 2012 08:01 et argos therapeutics to present at the stifel nicolaus 2012 healthcare conference - sep 4, 2012 12:45 et argos therapeutics receives fda approval of special protocol assessment for ags-003 phase 3 trial - jul 2, 2012 08:00 et more >> related news pharmaceuticals biotechnology bl. usual dose viagra order viagra online usa